La evidencia disponible en la literatura sobre el uso de enoxaparina en el manejo de la enfermedad tromboembólica venosa (ETV) en embarazadas permite considerar que se trata de un fármaco eficaz y seguro para la madre y el feto1,2,3,4,5, en el tratamiento y en la profilaxis de la ETV5,6.
Los estudios disponibles con enoxaparina avalan que:
1 Protocolos SEGO. Complicaciones tromboembólicas de la gestación. Prog Obstet Ginecol.2007;51(3):181-92.
2Muñoz AJ, Viñolas N, Cubedo R, Isla D. SEOM guidelines on thrombosis in cancer patients. ClinTransl Oncol. 2011;13(8):592-6.
3Samama MM. Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment. Drugs Aging. 2011;28(3):177-93.
4Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic Therapy in Neonates and Children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e737S-801S.
5Brenner B. Enoxaparin use in pregnancy: state of the art. Womens Health (Lon Enoxaparina en las GUÍAS CLÍNICAS d Engl) 2007;3(1):9-14.
6Narin C, Reyhanoglu H, Tülek B, et al. Comparison of diff erent dose regimens of enoxaparin in deep vein thrombosis therapy in pregnancy. Adv Ther.008;25(6):585-94.
7Bar J, Cohen-Sacher B, Hod M, Blickstein D, Lahav J, Merlob P. Low-molecular-weight heparin for thrombophilia in pregnant women. Int J Gynaecol Obstet 2000;69(3):209-13.
8Dimitrakakis C, Papageorgiou P, Papageorgiou I, et al. Absence of transplacental passage of the low molecular weight heparin enoxaparin.Haemostasis 2000;30(5):243-8.
9Casele H, Haney EI, James A, Rosene-Montella K, Carson M. Bone density changes in women who receive thromboprophylaxis in pregnancy. Am J Obstet Gynecol 2006;195(4):1109-13
10Fareed J, Hoppensteadt D, Walenga J, Iqbal O, Ma U, Jeske W, Sheikh T. Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice. Clin Pharmacokinet 2003;42(12):1043-57
11 Maslovitz S, Many A, Landsberg JA, Varon O, Lessing JB, Kupferminc MJ. The safety of low molecular weight heparin therapy during labor. J Matern Fetal Neonatal Med 2005;17(1):39-43.
12Hiscock RJ, Casey E, Simmons SW, Walker SP, Newell PA. Peak plasma anti-Xa levels after fi rst and third doses of enoxaparin in women receiving weight-based thromboprophylaxis following caesarean section: a prospective cohort study. Int J Obstet Anesth. 2013;22(4):280-8.
13Saeed CR, Frank JB, Pravin M, Aziz RH, Serasheini M, Dominique TG. A prospective trial showing the safety of adjusted-dose enoxaparin for thromboprophylaxis of pregnant women with mechanical prosthetic heart valves. Clin Appl Thromb Hemost. 2011;17(4):313-9.